Matching articles for "piperacillin/tazobactam"

Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections

   
The Medical Letter on Drugs and Therapeutics • July 22, 2024;  (Issue 1707)
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary...
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by designated susceptible microorganisms (see Spectrum of Activity). Exblifep is the first product that contains enmetazobactam to be approved in the US.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):117-8 | Show Full IntroductionHide Full Introduction

Antibacterial Drugs for Community-Acquired Pneumonia

   
The Medical Letter on Drugs and Therapeutics • January 25, 2021;  (Issue 1616)
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in...
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):10-5 | Show Full IntroductionHide Full Introduction

Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI

   
The Medical Letter on Drugs and Therapeutics • May 4, 2020;  (Issue 1597)
The FDA has approved cefiderocol (Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults...
The FDA has approved cefiderocol (Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults who have limited or no alternative treatment options.
Med Lett Drugs Ther. 2020 May 4;62(1597):65-8 | Show Full IntroductionHide Full Introduction

Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections

   
The Medical Letter on Drugs and Therapeutics • April 22, 2019;  (Issue 1570)
Eravacycline (Xerava – Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is...
Eravacycline (Xerava – Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is structurally similar to tigecycline (Tygacil, and generics), a broad-spectrum tetracycline approved by the FDA for IV treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired pneumonia. A higher rate of mortality has been reported with use of tigecycline compared to other antibacterial drugs; it should be used only when no suitable alternative is available.
Med Lett Drugs Ther. 2019 Apr 22;61(1570):61-3 | Show Full IntroductionHide Full Introduction

Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic

   
The Medical Letter on Drugs and Therapeutics • November 5, 2018;  (Issue 1559)
The FDA has approved the new aminoglycoside antibiotic plazomicin (Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against...
The FDA has approved the new aminoglycoside antibiotic plazomicin (Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug- resistant Enterobacteriaceae, including strains resistant to other aminoglycosides.
Med Lett Drugs Ther. 2018 Nov 5;60(1559):180-2 | Show Full IntroductionHide Full Introduction

Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection

   
The Medical Letter on Drugs and Therapeutics • June 18, 2018;  (Issue 1549)
The FDA has approved a fixed-dose combination of meropenem, a carbapenem antibiotic, and vaborbactam, a new beta-lactamase inhibitor (Vabomere – Melinta), for IV treatment of adults with complicated...
The FDA has approved a fixed-dose combination of meropenem, a carbapenem antibiotic, and vaborbactam, a new beta-lactamase inhibitor (Vabomere – Melinta), for IV treatment of adults with complicated urinary tract infections (UTIs) that are proven or strongly suspected to be caused by Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae spp. complex. Meropenem (Merrem, and generics) has been approved for years for treatment of complicated skin and skin structure infections, intra-abdominal infections, and bacterial meningitis. Resistance to meropenem and other carbapenems, mainly due to production of carbapenemases and other extended-spectrum beta-lactamases (ESBLs), has been increasing worldwide, particularly among Enterobacteriaceae. Vabomere is the first carbapenem/beta-lactamase inhibitor combination to be marketed in the US.
Med Lett Drugs Ther. 2018 Jun 18;60(1549):103-5 | Show Full IntroductionHide Full Introduction

Drugs for Common Bacterial Infections in Adults

   
The Medical Letter on Drugs and Therapeutics • October 23, 2017;  (Issue 1532)
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing...
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse effects.
Med Lett Drugs Ther. 2017 Oct 23;59(1532):171-7 | Show Full IntroductionHide Full Introduction

Alternatives to Fluoroquinolones

   
The Medical Letter on Drugs and Therapeutics • June 6, 2016;  (Issue 1496)
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects,...
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.
Med Lett Drugs Ther. 2016 Jun 6;58(1496):75-6 | Show Full IntroductionHide Full Introduction

Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015;  (Issue 1469)
The FDA has approved ceftazidime/avibactam (Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment...
The FDA has approved ceftazidime/avibactam (Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options. Ceftolozane/tazobactam (Zerbaxa – Cubist), another cephalosporin/beta-lactamase inhibitor combination, was approved in 2014.
Med Lett Drugs Ther. 2015 May 25;57(1469):79-80 | Show Full IntroductionHide Full Introduction

Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic

   
The Medical Letter on Drugs and Therapeutics • March 2, 2015;  (Issue 1463)
The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and...
The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in adults.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):31-3 | Show Full IntroductionHide Full Introduction

Drugs for Bacterial Infections

   
The Medical Letter on Drugs and Therapeutics • July 1, 2013;  (Issue 131)
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results...
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Treat Guidel Med Lett. 2013 Jul;11(131):65-74 | Show Full IntroductionHide Full Introduction

Drugs for Urinary Tract Infections

   
The Medical Letter on Drugs and Therapeutics • July 23, 2012;  (Issue 1395)
The most recent guidelines from the Infectious Diseases Society of America (IDSA) and its European counterpart on the choice of antimicrobials for treatment of uncomplicated urinary tract infections (UTIs)...
The most recent guidelines from the Infectious Diseases Society of America (IDSA) and its European counterpart on the choice of antimicrobials for treatment of uncomplicated urinary tract infections (UTIs) in non-pregnant women focus on the unnecessary use of fluoroquinolones to treat uropathogens that are increasingly becoming resistant to them. Resistance of Escherichia coli to ciprofloxacin in the US has increased from 3% in 2000 to 17.1% in 2010.
Med Lett Drugs Ther. 2012 Jul 23;54(1395):57-8 | Show Full IntroductionHide Full Introduction

Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • January 24, 2011;  (Issue 1356)
The FDA has approved ceftaroline fosamil (Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by...
The FDA has approved ceftaroline fosamil (Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), and for treatment of community-acquired bacterial pneumonia in adults. It is the first beta-lactam antibiotic approved for treatment of MRSA.
Med Lett Drugs Ther. 2011 Jan 24;53(1356):5-6 | Show Full IntroductionHide Full Introduction

Drugs for Bacterial Infections

   
The Medical Letter on Drugs and Therapeutics • June 1, 2010;  (Issue 94)
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter...
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Treat Guidel Med Lett. 2010 Jun;8(94):43-52 | Show Full IntroductionHide Full Introduction